NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 84 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $778 | +21.6% | 937,223 | +2.5% | 0.00% | 0.0% |
Q1 2023 | $640 | +5.4% | 914,613 | -23.4% | 0.00% | 0.0% |
Q4 2022 | $607 | -99.9% | 1,193,447 | -17.2% | 0.00% | 0.0% |
Q3 2022 | $923,000 | -44.5% | 1,442,067 | -10.7% | 0.00% | -50.0% |
Q2 2022 | $1,663,000 | -30.3% | 1,614,260 | +27.2% | 0.00% | -33.3% |
Q1 2022 | $2,386,000 | -41.3% | 1,268,969 | +50.4% | 0.00% | -40.0% |
Q4 2021 | $4,066,000 | -25.7% | 843,612 | +11.5% | 0.01% | -28.6% |
Q3 2021 | $5,472,000 | +2.9% | 756,892 | +31.4% | 0.01% | 0.0% |
Q2 2021 | $5,316,000 | -30.1% | 575,992 | -6.8% | 0.01% | -22.2% |
Q1 2021 | $7,607,000 | -29.3% | 617,937 | -19.0% | 0.01% | -25.0% |
Q4 2020 | $10,754,000 | +7.0% | 762,692 | -8.9% | 0.01% | +20.0% |
Q3 2020 | $10,046,000 | -41.8% | 837,137 | -19.5% | 0.01% | -33.3% |
Q2 2020 | $17,269,000 | +79.1% | 1,040,292 | +22.8% | 0.02% | +66.7% |
Q1 2020 | $9,640,000 | +8.8% | 847,092 | +17.8% | 0.01% | +28.6% |
Q4 2019 | $8,863,000 | +305.1% | 719,386 | -6.3% | 0.01% | +250.0% |
Q3 2019 | $2,188,000 | – | 767,841 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 1,156,200 | $10,672,000 | 1.77% |
ACT CAPITAL MANAGEMENT, LLC | 239,000 | $2,207,000 | 1.13% |
EcoR1 Capital, LLC | 2,358,804 | $21,772,000 | 0.81% |
Redmile Group, LLC | 3,919,235 | $36,175,000 | 0.54% |
Boxer Capital, LLC | 1,501,058 | $13,855,000 | 0.49% |
Baker Brothers Advisors | 3,821,740 | $35,275,000 | 0.16% |
Sio Capital Management, LLC | 38,312 | $354,000 | 0.09% |
Highland Private Wealth Management | 46,999 | $434,000 | 0.06% |
PERSONAL CFO SOLUTIONS, LLC | 23,710 | $219,000 | 0.04% |
Point72 Asset Management, L.P. | 883,102 | $8,151,000 | 0.04% |